|
Market Research Report
Pharmaceutical Pricing and Reimbursement in India
|
Pharmaceutical Pricing and Reimbursement in India published by Decision Resources, Inc. in September, 2009. This report consists of 38 Pages and the price starts from US $ 4600.
Abstract
Introduction
Faced with a dramatic slowdown in sales in mature pharmaceutical markets,
multinational pharmaceutical companies are looking to substantially increase
their sales in India and other emerging markets. The Indian market is growing
by more than 10% per year, but foreign companies will need to overcome signifi
cant obstacles to succeed in a market currently dominated by domestic
manufacturers.
Questions Answered in This Report
- The Indian population is forecast to grow from its present size of 1.2
billion to 1.7 billion in 2050. How will the age breakdown of the
population evolve over time? How will the balance between India' s urban and
rural populations change in the coming years?
- Only a minority of Indians have health insurance. What are the main
forms of health insurance? How do most Indians fund healthcare and
medications?
- The Indian government controls the prices of 74 scheduled medicines.
Which agents are subject to price control? How are prices of other drugs
regulated? How does the government penalize overcharging for drugs? How do
prices in India compare with prices in other markets? What pricing reforms is
the Indian government contemplating?
Scope
- Demographic trends: population breakdown by age and sex; population
breakdown by geographic distribution.
- Organization and funding of healthcare: overview of the Indian
healthcare system; access to healthcare; health insurance; out-of-pocket
expenditures.
- Pharmaceutical pricing: historical price controls; current price
control system; price adjustments; penalties for overcharging for drugs;
international price comparison; multinational companies' pricing strategies.
- Outlook and implications for the pharmaceutical industry:
encouraging commercial outlook; potential government reforms;
opportunities and threats for multinationals.
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Overview
- Demographic Trends
- Demographics by Age
- Demographics by Geographic Distribution
- Organization and Funding of Healthcare
- Overview
- Access to Healthcare
- Public Healthcare Infrastructure
- Corporate Hospital Chains
- Health Insurance
- Voluntary Individual Health Insurance
- Community-Based or Nongovernmental-Organization-Sponsored Health
Insurance
- Employer-Sponsored Coverage
- Government-Sponsored Insurance Programs
- Out-of-Pocket Expenditures
- Pharmaceutical Market Trends
- Historical Development of the Indian Pharmaceutical Market
- Recent Market Trends
- Intellectual Property Rights
- Regulation of the Indian Pharmaceutical Market
- Pharmaceutical Pricing
- Historical Price Controls
- Current Price Control System
- Scheduled Medicines
- Nonscheduled Medicines
- Price Adjustments
- Penalties for Overcharging for Drugs
- International Price Comparison
- Multinational Companies' Pricing Strategies in India
- Distribution Challenges
- Measures to Promote Greater Use of Inexpensive Generics
- Outlook and Implications for the Pharmaceutical Industry
- Encouraging Commercial Outlook Despite Signifi cant Challenges
- Potential Government Reforms
- New Price Controls for Patented Drugs
- Foreign Models for Price Setting
- Expansion of the List of Scheduled Medicines
- Monopoly Purchase of Certain Products
- Signifi cance for Drug Manufacturers
- Opportunities and Threats for Multinationals
Tables
- 1. Rural, Urban, and Major City Populations (thousands), 2008-2018
- 2. International Brands Launched in India, January 2005 to April 2009
- 3. Scheduled Medicines in India
- 4. Ex-Manufacturer Prices of Select Drugs in India and Other Major Markets
as a Percentage of U.S. Prices, 2008
Figures
- 1. Population Breakdown by Age and Sex
- 2. Population Growth, by Age-Group, 2008-2025
- 3. Urban Versus Rural Population Growth, 2008-2025
- 4. Number of Prices Fixed or Revised by the National Pharmaceutical
Pricing Authority, January 2000 to August 2009
- 5. Indian Prices of Select International Brands as a Percentage of the
Respective U.S. Prices, 2008
- 6. Indian Prices of Select International Brands and the Most Frequently
Prescribed Domestic Generic Equivalents
|
